- 3
- Episodes
- 7
- Ratings
- Monthly
- Cadence
- 2025
- First episode
About DIGESTING: The latest in IBD
DIGESTING keeps healthcare practitioners working with IBD patients up to date on the most important literature about inflammatory bowel disease. In each episode, gastroenterologists with deep expertise in inflammatory bowel disease discuss the latest studies and tell you what you need to know. It is produced by the BRIDGe Group.
- Publisher
- BRIDGe Group
- Category
- health & fitness · science
- Language
- en
- Explicit
- No
- First episode
- 21 Oct 2025
- Latest episode
- 12 Aug 2026
Latest episodes
3 episodes in the feed.
12 Aug 2026
Provocative Ideas That Could Change Practice
In this third episode, we discuss four inflammatory bowel disease (IBD) manuscripts published in the first quarter of 2026 that challenge established assumptions and introduce provocative ideas with the potential to change practice. Members of the Building Research in IBD Globally (BRIDGe) group distill the essential takeaways from these papers for practicing gastroenterologists, APPs, and IBD professionals who want a concise, clinically useful review of the latest literature. The BRIDGe group bridgeibd.com — founded in 2006 — is a collaboration of 14 global IBD experts across three continents and four countries. With a shared goal of improving patient-centered care, the group collectively follows more than 10,000 patients with IBD and leads collaborative research shaping the future of treatment. What You'll Learn from this Episode: How appendectomy performed alongside ongoing advanced therapy may induce remission in biologic-exposed ulcerative colitis and challenge the reflex to switch therapies after treatment failure. What the emerging evidence suggests about the efficacy, safety, and metabolic impact of GLP-1 receptor agonists in patients with IBD. Why disease location may meaningfully influence the effectiveness of advanced therapies in Crohn's disease, with ileal disease appearing harder to treat than isolated colonic disease. How long-term outcomes after ileocaecal resection compare with infliximab in ileal Crohn's disease and what that means for earlier surgical decision-making. Featured Contributors: Dr. Peter Irving — Guy's and St. Thomas' (London, UK) Dr. Gil Melmed — Cedars-Sinai Medical Center (Los Angeles, CA) Dr. Krisztina Gecse — Amsterdam University Medical Center (Amsterdam, Netherlands) and Guy's and St. Thomas' (London, UK) Dr. Corey Siegel — Dartmouth Health (Lebanon, NH) Articles Reviewed: Visser E, Reijntjes MA, Heuthorst L, Stellingwerf ME, West R, van Dongen K, Crolla RMPH, van Dieren S, van der Bilt JDW, Bemelman WA, D'Haens GR, Buskens CJ; COSTA Study Group. Appendicectomy versus switching to a JAK inhibitor in inducing remission in patients with active ulcerative colitis after biologic therapy failure (COSTA): 1-year results of a multicentre, prospective, cohort study. Lancet Gastroenterol Hepatol. 2026 Mar;11(3):190-203. Link to article (https://pubmed.ncbi.nlm.nih.gov/41512889/). Maracle B, Quan S, Hamilton P, Shaikh A, Hazra D, Lorenzetti DL, Gold SL, Raman M, St-Pierre J. Systematic Review: Efficacy, Safety and Metabolic Outcomes of GLP-1 Receptor Agonists in Inflammatory Bowel Disease. Aliment Pharmacol Ther. 2026 Jan;63(1):17-39. PMID: 41319219. Link to article Lee HH, Yuan Y, Boland BS, Chang JT, Jairath V, Singh S. Efficacy of Advanced Therapies in Achieving Remission by Disease Location in Crohn's Disease: A Systematic Review and Meta-Analysis. Clin Gastroenterol Hepatol. 2025 Jul 23:S1542-3565(25)00615-9. PMID:4071275. Link to article Ponsioen CY, de Groof EJ, Eshuis EJ, Gardenbroek TJ, Bossuyt PMM, Hart A, D'Haens GR, Irving PM, van der Meulen-de Jong AE, Cheung Z, et al. Ileocaecal resection versus infliximab for ileal Crohn's disease: 10-year follow-up of the LIR!C trial. Lancet Gastroenterol Hepatol. 2024 Nov 29:S2468-1253(24)00378-3. PMID: 41724174. Link to article (https://pubmed.ncbi.nlm.nih.gov/41724174/) Episode Credits: This episode of DIGESTING was produced by David Boyer, who not only was patient enough to teach us how to make a podcast but skilled enough to allow us to sound somewhat professional. Additional thanks to Jennifer Greene as the BRIDGe program manager for keeping us in a straight line to get this done. Episode 3 of DIGESTING was sponsored by AbbVie. All content was developed independently by the BRIDGe group. Follow DIGESTING wherever you get your podcasts and check out more about BRIDGe at www.BRIDGeIBD.com (https://www.bridgeibd.com). We look forward to bringing you our next episode soon.
14 Apr 2026
Digesting the Guidelines
In this second episode, we discuss the American College of Gastroenterology (ACG) inflammatory bowel disease (IBD) guidelines that were published in the last quarter of 2025. While there were hundreds of studies published in IBD over this period, we believe it is important to understand the current tone of IBD management and what has changed from the last round of ACG guidelines that were published between 2017-2019. Members of the Building Research in IBD Globally (BRIDGe) Group distill the essential concepts and updates from these guidelines that every practicing gastroenterologist, APP and IBD professional needs to know right now. What You'll Learn from this Episode: How treatment guidelines and goals have evolved and treatment targets have been refined in IBD Review the dramatic expansion of therapeutic mechanisms in IBD and how to approach selection of agents for first line therapy and beyond The recommended use of advanced therapy at diagnosis in Crohn's disease and how to use new monitoring modalities in practice A practical approach to vaccination, screening for mental health disorders and other high impact health maintenance considerations The BRIDGe Group (https://www.bridgeibd.com/) — founded in 2006 — is a collaboration of 14 global IBD experts across three continents and four countries. With a shared goal of improving patient-centered care, the group collectively follows more than 10,000 patients with IBD and leads collaborative research shaping the future of treatment.Featured Contributors: Dr. Peter Irving - Guy's and St. Thomas' (London, UK) Dr. Gil Melmed - Cedars-Sinai Medical Center (Los Angeles, CA) Dr. Tom Ullman - Mount Sinai Medical Center (New York, NY) Dr. Corey Siegel - Dartmouth Health (Lebanon, NH) Articles Reviewed: Rubin DT, Ananthakrishnan AN, Siegel CA, Barnes EL, Long MD. ACG Clinical Guideline Update: Ulcerative Colitis in Adults. Am J Gastroenterol. 2025 Jun 3;120(6):1187‑1224. PMID: 41384833. Lichtenstein GR, Loftus EV, Afzali A, Long MD, Barnes EL, Isaacs KL, Ha CY. ACG Clinical Guideline: Management of Crohn's Disease in Adults. Am J Gastroenterol. 2025 Jun 3;120(6):1225-1264. PMID: 40701562 Farraye FA, Melmed GY, Lichtenstein GR, Barnes EL, Limketkai BN, Caldera F, Kane SV. ACG Clinical Guideline Update: Preventive Care in Inflammatory Bowel Disease. Am J Gastroenterol. 2025 Jul 2;120(7):1447‑1473. PMID: 40701559 Episode Credits: This episode of DIGESTING was produced by David Boyer, who not only was patient enough to teach us how to make a podcast but skilled enough to allow us to sound somewhat professional. Additional thanks to Jennifer Greene as the BRIDGe program manager for keeping us in a straight line to get this done. Episode 2 of DIGESTING was sponsored by Abbvie. All content was developed independently by the BRIDGe group. Follow DIGESTING wherever you get your podcasts and check out more about BRIDGe at www.BRIDGeIBD.com [bridgeibd.com]. We look forward to bringing you our next episode soon.
21 Oct 2025
Tell Me What I Need to Know
In this premiere episode, we break down the most relevant and practice-changing research articles in inflammatory bowel disease from January through March 2025. With hundreds of studies published each month across major international journals, members of the Building Research in IBD Globally (BRIDGe) group distill the essential findings every practicing gastroenterologist, APP, and IBD professional needs to know right now. The BRIDGe group (https://www.BRIDGeIBD.com) — founded in 2006 — is a collaboration of 14 global IBD experts across three continents and four countries. With a shared goal of improving patient-centered care, the group collectively follows more than 10,000 patients with IBD and leads collaborative research shaping the future of treatment. What You'll Learn from This Episode: The five key IBD studies from early 2025 that may immediately impact clinical decision-making How global collaboration helps clinicians stay ahead of emerging data Insights into the literature selection process led by BRIDGe fellows Quick, clinically relevant perspective on practice-changing research Featured Contributors: Dr. Laura Raffals – Mayo Clinic (Rochester, MN) Dr. Peter Irving – Guy's and St. Thomas' (London, UK) Dr. Gil Melmed – Cedars-Sinai Medical Center (Los Angeles, CA) Dr. Corey Siegel – Dartmouth Health (Lebanon, NH) BRIDGe Fellows Who Curated the Articles: Mayo Clinic: Dr. Siri Urquhart and Dr. Katie Dunleavy Guy's and St. Thomas': Dr. Xin Yi Choon and Dr. Yvonne Abbey Cedars-Sinai: Dr. Felix Zhou and Dr. Rajsavi Anand Dartmouth: Dr. Hannah Systrom and Dr. Jamie Horrigan Articles Reviewed: Shehab M, Alrashed F, Alsayegh A, Aldallal U, Ma C, Narula N, Jairath V, Singh S, Bessissow T. Comparative Efficacy of Biologics and Small Molecule in Ulcerative Colitis: A Systematic Review and Network Meta-analysis. Clin Gastroenterol Hepatol. 2025 Feb;23(2):250-262. doi: 10.1016/j.cgh.2024.07.033. Epub 2024 Sep 5. PMID: 39182898. Gao L, Fang K, Dong X, Bai J, Liu K, Wang Y, Wang M, Han Y, Liu Z. Additional Yield of Random Biopsy in Patients With Inflammatory Bowel Disease: A Systematic Review and Meta-Analysis (https://pubmed.ncbi.nlm.nih.gov/38972436/). Clin Gastroenterol Hepatol. 2025 Mar;23(4):542-554.e21. doi: 10.1016/j.cgh.2024.05.045. Epub 2024 Jul 5. PMID: 38972436. Gisbert JP, Chaparro M. Janus kinase inhibitors in the management of acute severe ulcerative colitis: a comprehensive review. J Crohns Colitis. 2025 Feb 4;19(2):jjaf021. doi: 10.1093/ecco-jcc/jjaf021. PMID: 39886994. Lowell JA, Sharma G, Swaminath A, Sultan K. Pharmacologic Anticoagulation Is Associated With a Lower Risk of Recurrent Venous Thromboembolic Events During Janus Kinase Inhibitor Use for Patients With a Prior Thrombosis. Inflamm Bowel Dis. 2025 Mar 3;31(3):725-732. doi: 10.1093/ibd/izae100. PMID: 38704439. Systrom HK, Rai V, Singh S, Baidoo L, Cheifetz AS, Devlin SM, Gecse KB, Irving PM, Kaplan GG, Kozuch PL, Ullman T, Sparrow MP, Melmed GY, Siegel CA. When Perfect Is the Enemy of Good: Results of a RAND Appropriateness Panel on Treat to Target in Asymptomatic Inflammatory Bowel Disease. Am J Gastroenterol. 2025 Feb 1;120(2):420-430. doi: 10.14309/ajg.0000000000002964. Epub 2024 Jul 15. PMID: 39008539. Other Article Discussed: Awais D, Siegel CA, Higgins PD. Modelling dysplasia detection in ulcerative colitis: clinical implications of surveillance intensity. Gut. 2009 Nov;58(11):1498-503. doi: 10.1136/gut.2008.169714. Epub 2009 Aug 2. PMID: 19651634. Episode Credits: This episode of DIGESTING was produced by David Boyer, who not only was patient enough to teach us how to make a podcast but skilled enough to allow us to sound somewhat professional. Additional thanks to Jennifer Greene as the BRIDGe program manager for keeping us in a straight line to get this done. Follow DIGESTING wherever you get your podcasts and check out more about BRIDGe at www.BRIDGeIBD.com (http://www.BRIDGeIBD.com). We look forward to bringing you our next episode soon.
Reach and audience
Public platform figures. Ratings count people who left a rating, not total listeners.
- Apple Podcasts (US)
- 5.0 / 5
- 7 ratings
Contact DIGESTING: The latest in IBD
- Guest appearances
- Does not typically book guests
Based on episode analysis; this does not confirm that the show is currently accepting guests.
Shows with a similar audience
Host of DIGESTING: The latest in IBD?
Claim your podcast to manage its listing and keep your show details accurate.
Pod Engine is an independent podcast discovery and analytics service and is not affiliated with or endorsed by this podcast. Artwork and show content belong to their owners. Full legal notice.
Explore this show
Podcast research with Pod Engine